UK’s NICE Reverses View On Afinitor In Renal Cancer After Novartis Cuts Price
Executive Summary
UK HTA body NICE says it is now backing Novartis’s Afinitor for the treatment of some people with advanced kidney cancer on the publicly funded National Health Service after the Swiss group offered a price discount. This changes the availability in England and Wales of the drug, which was previously only available through the controversial Cancer Drugs Fund. NICE has now given the go-ahead for routine commissioning of 13 cancer drugs/indications that were listed on the CDF before it was revamped last year.
You may also be interested in...
Patient Engagement Helped Roche’s Kadcyla Get Reimbursement In Scotland
Roche has finally gained a positive recommendation from a health technology assessment body in the UK for its advanced breast cancer therapy, Kadcyla. The Scottish Medicines Consortium gave the product the all-clear after the quality-of-life benefits were highlighted by patients and doctors. It’s future in England is still unclear.
BMS’ Sprycel Is Latest CDF Drug To Get NICE Clearance For Routine NHS Use
NICE has given the go-ahead for routine NHS commissioning of seven cancer drugs/indications that were listed on the Cancer Drugs Fund before it was overhauled earlier this year. A total of 35 product indications are up for reappraisal under the program.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.